Four MicroRNAs Signature for Survival Prognosis in Colon Cancer Using TCGA Data

Overview

Journal Sci Rep

Specialty Science

Date 2016 Dec 16

PMID 27974852

Citations 20

Authors

Jian Xu

Jian Zhao

Rui Zhang

Affiliations

Soon will be listed here.

Abstract

This study aims to develop microRNA expression signature for colon cancer survival prognosis based on the Cancer Genomic Common database. miRNAs levels between colon cancer and non-cancer tissues were screened by t-test (p < 0.05). Kaplan-Meier survival method was used to discriminate survival significant miRNAs, followed by miRNAs index accumulation to power the miRNAs-survival reliability. In the end, we test the selected miRNAs in HT126 colon cancer cells to validate its anti-cancer effect. The study identified a 84-miRNAs signature. Of the above 84 miRNAs, we got four miRNAs which were survival associated by using ROC curve method and Kaplan-Meier survival method (p < 0.001). The result showed that low risk group had quite a low death rate, the survival rate was over 80%. The high risk group had survival rate lower than 20%, which was also extremely lower than the overall survival rate. In the HT126 cells study, cell growth assay showed miR-130a sponge inhibited colon cancer cells growth and sensitized the anti-cancer drug effect of 5-FU to blocked cancer cell growth. We developed a prognostic 4-microRNA expression signature for colon cancer patient survival, and validated miR-130a sponge could sensitized 5-FU anti-cancer effect.

Citing Articles

A Highly Sensitive Urinary Exosomal miRNAs Biosensor Applied to Evaluation of Prostate Cancer Progression.

Chiou Y, Yu K, Pang S, Yang Y, Pang S, Weng W Bioengineering (Basel). 2022; 9(12).

PMID: 36551009 PMC: 9774101. DOI: 10.3390/bioengineering9120803.

A Three-Genes Signature Predicting Colorectal Cancer Relapse Reveals LEMD1 Promoting CRC Cells Migration by RhoA/ROCK1 Signaling Pathway.

Zhang H, Xu C, Jiang F, Feng J Front Oncol. 2022; 12:823696.

PMID: 35619906 PMC: 9127067. DOI: 10.3389/fonc.2022.823696.

Construction of five microRNAs prognostic markers and a prognostic model for clear cell renal cell carcinoma.

Zhou Q, Zhang Z, Ang X, Hu C, Ouyang J Transl Cancer Res. 2022; 10(5):2337-2353.

PMID: 35116550 PMC: 8797919. DOI: 10.21037/tcr-21-37.

Nanomaterial-Based Fluorescence Resonance Energy Transfer (FRET) and Metal-Enhanced Fluorescence (MEF) to Detect Nucleic Acid in Cancer Diagnosis.

Choi J, Ha T, Shin M, Lee S, Choi J Biomedicines. 2021; 9(8).

PMID: 34440132 PMC: 8392676. DOI: 10.3390/biomedicines9080928.

Competing Endogenous RNA in Colorectal Cancer: An Analysis for Colon, Rectum, and Rectosigmoid Junction.

Vieira L, Jorge N, de Sousa J, Setubal J, Stadler P, Walter M Front Oncol. 2021; 11:681579.

PMID: 34178670 PMC: 8222815. DOI: 10.3389/fonc.2021.681579.

References

Egawa H, Jingushi K, Hirono T, Ueda Y, Kitae K, Nakata W . The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN. Sci Rep. 2016; 6:20574. PMC: 4738343. DOI: 10.1038/srep20574. View

Khare S, Verma M . Epigenetics of colon cancer. Methods Mol Biol. 2012; 863:177-85. DOI: 10.1007/978-1-61779-612-8_10. View

Yan W, Li R, Liu Y, Yang P, Wang Z, Zhang C . MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget. 2014; 5(24):12908-15. PMC: 4350338. DOI: 10.18632/oncotarget.2679. View

Szafranska A, Davison T, Shingara J, Doleshal M, Riggenbach J, Morrison C . Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling. J Mol Diagn. 2008; 10(5):415-23. PMC: 2518736. DOI: 10.2353/jmoldx.2008.080018. View

Lewis B, Burge C, Bartel D . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. DOI: 10.1016/j.cell.2004.12.035. View

Wang E, Zaman N, Mcgee S, Milanese J, Masoudi-Nejad A, OConnor-Mccourt M . Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. Semin Cancer Biol. 2014; 30:4-12. DOI: 10.1016/j.semcancer.2014.04.002. View

Zhu Z, Sun B, Ma Y, Shao J, Long H, Zhang X . Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol. 2009; 27(7):1091-9. DOI: 10.1200/JCO.2008.16.6991. View

Cho M, So I, Chun J, Jeon J . The antitumor effects of geraniol: Modulation of cancer hallmark pathways (Review). Int J Oncol. 2016; 48(5):1772-82. PMC: 4809657. DOI: 10.3892/ijo.2016.3427. View

Duan J, Zhang H, Qu Y, Deng T, Huang D, Liu R . Onco-miR-130 promotes cell proliferation and migration by targeting TGFβR2 in gastric cancer. Oncotarget. 2016; 7(28):44522-44533. PMC: 5190115. DOI: 10.18632/oncotarget.9936. View

10.

Bertero T, Cottrill K, Lu Y, Haeger C, Dieffenbach P, Annis S . Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit. Cell Rep. 2015; 13(5):1016-32. PMC: 4644508. DOI: 10.1016/j.celrep.2015.09.049. View

11.

Hainaut P, Plymoth A . Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol. 2012; 25(1):50-1. DOI: 10.1097/CCO.0b013e32835b651e. View

12.

Zlobec I, Steele R, Terracciano L, Jass J, Lugli A . Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2006; 60(10):1112-6. PMC: 2014838. DOI: 10.1136/jcp.2006.044537. View

13.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

14.

Lopez-Sanchez C, Franco D, Bonet F, Garcia-Lopez V, Aranega A, Garcia-Martinez V . Negative Fgf8-Bmp2 feed-back is regulated by miR-130 during early cardiac specification. Dev Biol. 2015; 406(1):63-73. DOI: 10.1016/j.ydbio.2015.07.007. View

15.

Fabian M, Sonenberg N, Filipowicz W . Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010; 79:351-79. DOI: 10.1146/annurev-biochem-060308-103103. View

16.

Wong N, Khwaja S, Baker C, Gay H, Thorstad W, Daly M . Prognostic microRNA signatures derived from The Cancer Genome Atlas for head and neck squamous cell carcinomas. Cancer Med. 2016; 5(7):1619-28. PMC: 4944889. DOI: 10.1002/cam4.718. View

17.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

18.

Ward P, Thompson C . Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012; 21(3):297-308. PMC: 3311998. DOI: 10.1016/j.ccr.2012.02.014. View

19.

Osaki M, Okada F, Ochiya T . miRNA therapy targeting cancer stem cells: a new paradigm for cancer treatment and prevention of tumor recurrence. Ther Deliv. 2015; 6(3):323-37. DOI: 10.4155/tde.14.122. View

20.

Wang M, Wen T, He L, Li C, Zhu W, Trishul N . A six-microRNA set as prognostic indicators for bile duct cancer. Int J Clin Exp Med. 2016; 8(10):17261-70. PMC: 4694218. View